Published: October 2023
The growing prevalence of rare and chronic diseases and the burgeoning demand for plasma-derived therapies have necessitated the advancements in blood plasma fractionation technologies in order to ensure a sustainable supply We analyzed over 35 plasma fractionation companies that have the capability to perform in-house / contract services related to plasma fractionation. In this article, discover six leading plasma fractionators.
Plasma being one of the key components of blood has been used therapeutically for over 100 years. The earliest use of blood plasma dates back to the World War II, when an American biochemist, Dr. Edwin Cohn discovered a fractionate process to separate albumin from other plasma components, in order to help soldiers suffering from burn shock.
The intricate composition of blood plasma was first identified by the Nobel Prize laureate Arne Tiselius and Theodor Svedberg, which resulted in the identification of several plasma fractionation proteins. Amongst all the plasma proteins, four proteins namely, albumin, immunoglobulin G, coagulation factor VIII, and coagulation factor IX, have gained significant importance at commercial scale, owing to their substantial demand from patients. Over the years, plasma therapies have been used for the treatment of patients suffering from rare and chronic diseases. The growing prevalence of aforementioned disorders has demanded the approval of more such innovative therapeutic treatments. In fact, till date, over 95 plasma-derived therapies have already been approved. Moreover, plasma fractionators are taking several initiatives to fulfill the growing demand for such therapies. Examples of these initiatives include growing number of partnerships and expansions. Recently, in May 2023, PlasmaGen Biosciences announced the opening of a new plant for the manufacturing of plasma-derived proteins in Kolar. The facility is spread across 8 acres and has an initial capacity of processing ~500,000L of plasma annually. Further, considering the growing demand for plasma derived therapies and growing number of partnerships and expansions, we believe that this market is likely to witness a steady growth over the coming years.
The companies developing blood and plasma based products are looking for expansions in new markets, specifically within Africa and Asia. These regions have hard to reach areas / locations and more recently a number of medical drone manufacturers are developing delivery drones for supply of medical supplies to such regions. Although not implemented yet, we believe such developments will drive the market for plasma products in the future.
Roots Analysis has conducted an exhaustive study on Plasma Fractionation Market featuring the current market landscape and future opportunity for the companies having capability to perform plasma fractionation, over a span of 12 years.
The top six companies performing in-house or contract services for plasma fractionation are listed below (in alphabetical order):
1. Baxter
2. CSL
3. Grifols
4. Kedrion
5. Octapharma
6. Takeda Pharmaceutical Company
Interested in exploring all 35+ Plasma Fractionation Companies?
This article highlights six leading plasma fractionation companies in North America, Europe and Asia-Pacific to watch out for in 2023. It presents details related to the key industry players engaged in the market landscape of plasma fractionation. The companies presented in this article are large companies and have plasma fractionation facilities in more than one region. It is essential to note that the selection of top players can differ substantially according to the defined criteria(s).
 |
Baxter is a US based company with a strong foothold in the healthcare industry. It has a diverse product portfolio, of biotechnology products, medical devices, and pharmaceuticals, along with plasma collection and fractionation. Through the extraction of vital protein components from blood plasma, it manufactures essential plasma therapies to address immune deficiencies, trauma, and other critical diseases. These products are then used across patients’ homes, hospitals, physician offices, and other sites for critical care.
Location of Plasma Fractionation Facilities
The list of facilities through which the company performs / offers plasma fractionation are mentioned below:
Type of Company – In-house Fractionator and Contract Service Provider
Recent Developments and Future Outlook
In 2023, the company participated in various conferences such as Jefferies Healthcare Conference, BofA Securities 2023 Health Care, AORN Global Surgical Conference and Expo 2023, in Raymond James 2023, and in 41st Annual J.P. Morgan Healthcare Conference. However, the company has not explicitly mentioned the purpose of participating in these conferences.
Further information related to the company’s plasma fractionation capabilities, financial performance, and recent developments is available in the full report.
 |
Grifols is a pharmaceutical company dedicated to improving the health and well-being of individuals worldwide. It operates in over 110 countries, delivering innovative healthcare services and solutions, with its expertise in plasma-derived medicinal products and transfusion medicine. These are used to treat a wide range of disorders and illnesses, including hematological disorders, hepatic disorders, immunological disorders, infectious diseases, intensive care, neurological disorders, and pulmonary disorders. In addition, the firm has over 390 plasma donation centers spanning across North America, Europe, Africa, Middle East, and Asia-Pacific. The firm is a pioneer in the plasma industry.
It is worth highlighting that Grifols actively supported Ukraine during the conflict by sending essential humanitarian aid. The company collaborated with humanitarian and relief agencies to ensure the delivery of critical medicines and diagnostic solutions, including anti-tetanus immunoglobulin, blood clotting factors, glucose, and saline solutions, to patients and healthcare professionals.
Location of Plasma Fractionation Facilities
The list of facilities through which the company performs / offers plasma fractionation are mentioned below:
California, US
North Caroline, US
Canada
Spain
Germany
Ireland
Egypt
Type of Company – In-house Fractionator and Contract Service Provider
Recent Developments and Future Outlook
In January 2022, as part of the alliance between Grifols and Egypt’s National Service Projects Organization, the company started receiving donations through the plasma collection centers, in Cairo, Egypt. It is worth highlighting that the first shipment of this collected plasma from Grifols Egypt reached Barcelona, Spain, in February 2023, where it is being used to manufacture lifesaving plasma medicines and was anticipated to get shipped to Egyptian hospitals by June 2023. The company also announced its plans to acquire blood plasma collection centre from Canadian Plasma Resources. At present the company will buy the plasma collected at these centres with plans to acquire the facilities by 2025.1
In March 2023, the company collaborated with Selagine for the development of immunoglobulin eye drops to treat dry eye disease. In order to demonstrate global leadership, the company is anticipated to forge alliances between plasma industry and the public sector to ensure domestic plasma self-sufficiency.
Further information related to the company’s plasma fractionation capabilities, financial performance, and recent developments is available in the full report.
 |
Kedrion is a global biopharmaceutical company, engaged in the development of plasma-derived products. Further, the firm specializes in the collection and fractionation of blood plasma for the development and distribution of plasma-derived therapies in more than 100 countries. These therapies are used to treat various diseases such as hemophilia, primary immunodeficiencies, and Rh sensitization. Further, the company operates across five countries, with seven production plants and plasma collection centers in the US and Czech Republic.
It is worth noting that in September 2022, Kedrion merged with Bio Products Laboratory (BPL), to combat rare and extremely rare conditions through plasma-derived medicines.
Location of Plasma Fractionation Facilities
The list of facilities through which the company performs / offers plasma fractionation are mentioned below:
Type of Company – In-house Fractionator and Contract Service Provider
Recent Developments and Future Outlook
In July 2023, the company announced approval of Bio Products Laboratory’s human albumin product for sales in China.2 In February 2023, the firm participated in Rare Disease Day, to raise awareness for individuals and families affected by rare diseases. Through this, the company emphasized equal health access, improved diagnosis and ensuring access to treatment for the 300 million people worldwide living with rare diseases. Furthermore, on the occasion of World Hemophilia Day (observed annually on April 17th), Kedrion affirmed its commitment to support the patients affected by hemophilia and other coagulation disorders. In March 2023, the company entered into an agreement with Portugal government for manufacturing plasma-based therapies. Further, in January 2022, the firm signed an industrial cooperation agreement with LFB to increase the availability of immunoglobulin for patients in France. Last year, in December 2022, the company announced the acquisition of UNICAplasma and UNICAplasma Morava to add five plasma collection centers in the Czech Republic. These acquisitions were likely to increase the annual plasma collection capacity of company by nearly 70,000 liters. Looking at the number of initiatives taken by the company in recent past, the company is likely to undertake more such initiatives in order to accommodate the growing demands of its global network of clients.
Further information related to the company’s plasma fractionation capabilities, financial performance, and recent developments is available in the full report.
 |
Octapharma is a leading healthcare company specializing in the production and distribution of high-quality plasma-derived products and recombinant therapeutic proteins. The company claims to be one of the largest human protein product manufacturers and develops protein-based therapeutics derived from human cell lines and human plasma, sourced from over 190 in-house plasma donation centers. Moreover, plasma therapies are distributed to nearly 120 countries to treat patients affected by various diseases, including indications related to hematology, immunotherapy, and critical care.
Location of Plasma Fractionation Facilities
The list of facilities through which the company performs / offers plasma fractionation are mentioned below:
Recent Developments and Future Outlook
In February 2023, the company provided humanitarian support to Turkey by providing lifesaving plasma products and supplies. In addition, in the same month, the company received the European medical authorities (EMA) approval for lyophilized presentation of the well-established octaplasLG. We anticipate the company to obtain more of such regulatory approvals for its extensive pipeline of plasma-derived therapies, to provide effective treatments.
Further information related to the company’s plasma fractionation capabilities, financial performance, and recent developments is available in the full report.
 |
Commonwealth Serum Laboratories (CSL) is a leading biotechnology company that specializes in the development of vital medicines. The company’s product portfolio includes a wide range of therapies and vaccines used to address critical medical conditions such as dialysis, hemophilia, immune deficiencies, influenza, iron deficiency, and renal disorders. The company operates through four business segments, namely CSL Behring, CSL Plasma, CSL Seqirus, and CSL Vifor, each contributing their expertise to the company's success.
CSL Behring and CSL Plasma are responsible for managing the company's plasma services. With over 350 plasma collection centers across the US, Europe, and China, CSL Plasma has been a reliable supplier plasma for CSL Behring. In turn, CSL Behring fractionates and distributes vital plasma-derived medicinal products to more than 100 countries. With advanced technologies for plasma fractionation, CSL is well-equipped to address various medical conditions related to immunology, hematology, cardiovascular health, metabolism, and respiratory disorders, through plasma therapies.
Location of Plasma Fractionation Facilities
The list of facilities through which the company performs / offers plasma fractionation are mentioned below:
Recent Developments and Future Outlook
In April 2023, CSL plasma, the plasma collection segment of CSL opened its 320th plasma collection center in Kankakee, Illinois and company announced receival of the FDA approval for 50mL/10gm prefilled syringe for Hizentra. In addition, in March 2023, the company invested USD 470 million to establish new plasma fractionation facility at its site located in Marburg, Germany. In December 2022, the company invested USD 100 million for the establishment of a new plasma fractionation facility in Victoria, Australia, with a capability to fractionate more than 9 million Liters plasma annually, to meet the increasing demands for plasma therapies.
Further, in October 2022, the firm announced the expansion of its plasma collection capacities through the addition of new centers in Stockton and Hayward, California. Followed by this, the firm received manufacturing and marketing authorization from MHLW, in Japan, for its plasma-derived, human C1-esterase inhibitor concentrate, known as Berinert S.C. Injection 2000, to prevent acute hereditary angioedema (HAE) attacks, in September 2022. We expect the firm to undertake additional expansion and investment based initiatives in order to expand its plasma related services over the coming years.
Further information related to the company’s plasma fractionation capabilities, financial performance, and recent developments is available in the full report
 |
Takeda is a global biopharmaceutical company headquartered in Japan, dedicated to discovering and delivering transformative treatments. With a focus on gastroenterology, hematology, neuroscience, oncology, and rare genetics, the company conducts research and development to advance therapies for immune and inflammatory diseases. In addition, the firm is engaged in providing plasma-derived therapies and vaccines to address critical healthcare needs.
The company claims to be one of the top three plasma organizations globally and has comprehensive end-to-end capabilities spanning the entire plasma value chain. It is worth highlighting that the company has over 230 state-of-the-art plasma collection centers across the US and Europe, upholding stringent safety standards.
Location of Plasma Fractionation Facilities
The list of facilities through which the company performs / offers plasma fractionation are mentioned below:
Recent Developments and Future Outlook
In October 2022, the company signed a partnership with the United Nations Institute for Training and Research (UNITAR) to create an impartial UN-based platform where stakeholders can congregate to solve plasma and plasma-derived therapy shortfalls. Further, in February 2022, the company entered in a manufacturing agreement with National Resilience to support the development and manufacturing of the former company’s plasma-derived medicines portfolio.
In addition, in March 2023, the company invested JPY 100 billion to establish new plasma fractionation facility at its site located in Osaka, Japan.3 While in September 2022, the company invested EUR 300 million for the establishment of a new plasma production facility in Lessines, Belgium to boost its plasma therapies manufacturing capabilities. Looking at the number of initiatives undertaken by the company in the recent past, the company is anticipated to grasp more such opportunities wherein they can expand their existing plasma-derived products portfolio.
Further information related to the company’s plasma fractionation capabilities, financial performance, and recent developments is available in the full report.
The above presentation features six promising plasma fractionators selected from a pool of over 35 plasma fractionators that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.
Ankita_Kashyap is a business research and competitive intelligence professional with over four years of experience in the pharmaceutical and healthcare industry. As an associate at Roots Analysis, she has authored numerous trending multidisciplinary market research reports, including viral vectors, aseptic manufacturing, continuous manufacturing, bioprinting, ADC technology, membrane filtration, liquid biopsy and more. She has continuously provided her valuable insights into the latest innovations in healthcare. During her professional journey, she has acquired good analytical skills in the pharmaceutical and biopharmaceutical industry, which in turn has contributed to the firm’s intellectual capital. This has allowed our clients to make informed decisions in the dynamic pharmaceutical landscape. She embarked upon her career with us. She started her journey as a business analyst with Roots Analyst and in such a short span of time, she has demonstrated amazing dedication. Till date, she has contributed to over 20 research reports.
Ankita holds a Master’s degree in Pharmacology from Chitkara University. While pursuing her education, she contributed her skills for various review and research literature. The impact of her learnings can be found in her professional blogs, market research reports and social media profiles.
Sources 1: https://www.theglobeandmail.com/canada/article-spains-grifols-to-acquire-lone-canadian-plasma-collector-to-fulfill/
Sources 2: https://www.prnewswire.com/news-releases/kedrions-global-portfolio-expands-to-china-to-supply-human-albumin-301875789.html
Sources 3: https://www.takeda.com/newsroom/newsreleases/2023/takeda-to-invest-100-billion-jpy-in-new-pdt-manufacturing-facility/
MEDIA CITATIONS
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES
.png)
